Insider Transactions in Q1 2023 at Pfizer Inc (PFE)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2023
|
William Pao Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
22,095
-18.43%
|
$883,800
$40.8 P/Share
|
|
Mar 15
2023
|
Jennifer B. Damico SVP & Controller |
SELL
Open market or private sale
|
Direct |
9,912
-52.4%
|
$396,480
$40.02 P/Share
|
|
Feb 27
2023
|
Payal Sahni Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,297
-5.32%
|
$51,880
$40.78 P/Share
|
|
Feb 27
2023
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,427
-6.89%
|
$57,080
$40.78 P/Share
|
|
Feb 27
2023
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,081
-3.67%
|
$123,240
$40.78 P/Share
|
|
Feb 25
2023
|
Payal Sahni Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,753
-9.96%
|
$241,626
$42.59 P/Share
|
|
Feb 25
2023
|
Payal Sahni Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
8,921
+22.85%
|
$196,262
$22.89 P/Share
|
|
Feb 25
2023
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
7,191
-13.66%
|
$302,022
$42.59 P/Share
|
|
Feb 25
2023
|
Jennifer B. Damico SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
11,150
+28.56%
|
$245,300
$22.89 P/Share
|
|
Feb 25
2023
|
Angela Hwang President, Global Biopharma |
SELL
Payment of exercise price or tax liability
|
Direct |
14,763
-18.07%
|
$620,046
$42.59 P/Share
|
|
Feb 25
2023
|
Angela Hwang President, Global Biopharma |
BUY
Exercise of conversion of derivative security
|
Direct |
20,273
+31.28%
|
$446,006
$22.89 P/Share
|
|
Feb 25
2023
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
9,144
-5.02%
|
$384,048
$42.59 P/Share
|
|
Feb 25
2023
|
Michael Mc Dermott Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,178
+13.22%
|
$311,916
$22.89 P/Share
|
|
Feb 25
2023
|
Rady A Johnson Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
22,836
-10.27%
|
$959,112
$42.59 P/Share
|
|
Feb 25
2023
|
Rady A Johnson Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
33,654
+22.42%
|
$740,388
$22.89 P/Share
|
|
Feb 25
2023
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
54,868
-14.05%
|
$2,304,456
$42.59 P/Share
|
|
Feb 25
2023
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
72,984
+25.87%
|
$1,605,648
$22.89 P/Share
|
|
Feb 25
2023
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
43,419
-12.32%
|
$1,780,179
$41.75 P/Share
|
|
Feb 25
2023
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
26,389
-16.34%
|
$1,081,949
$41.75 P/Share
|
|
Feb 25
2023
|
Mikael Dolsten President R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
37,078
-9.48%
|
$1,520,198
$41.75 P/Share
|
|
Feb 24
2023
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
360
-2.15%
|
$14,760
$41.75 P/Share
|
|
Feb 23
2023
|
Jennifer B. Damico SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
3,103
+15.64%
|
-
|
|
Feb 22
2023
|
Angela Hwang President, Global Biopharma |
SELL
Payment of exercise price or tax liability
|
Direct |
42,759
-35.43%
|
$1,838,637
$43.04 P/Share
|
|
Feb 22
2023
|
Angela Hwang President, Global Biopharma |
BUY
Exercise of conversion of derivative security
|
Direct |
57,032
+45.97%
|
$1,710,960
$30.17 P/Share
|
|
Feb 22
2023
|
Sally Susman Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
59,298
-16.01%
|
$2,549,814
$43.04 P/Share
|
|
Feb 22
2023
|
Sally Susman Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
76,043
+28.0%
|
$2,281,290
$30.17 P/Share
|
|
Feb 22
2023
|
Payal Sahni Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
11,465
-18.57%
|
$492,995
$43.04 P/Share
|
|
Feb 22
2023
|
Payal Sahni Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,209
+31.76%
|
$456,270
$30.17 P/Share
|
|
Feb 22
2023
|
Michael Mc Dermott Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
10,036
-5.74%
|
$431,548
$43.04 P/Share
|
|
Feb 22
2023
|
Michael Mc Dermott Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
13,307
+13.01%
|
$399,210
$30.17 P/Share
|
|
Feb 22
2023
|
Douglas M Lankler Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
19,878
-10.96%
|
$834,876
$42.38 P/Share
|
|
Feb 22
2023
|
Rady A Johnson Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
23,737
-11.54%
|
$1,020,691
$43.04 P/Share
|
|
Feb 22
2023
|
Rady A Johnson Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
31,558
+22.85%
|
$946,740
$30.17 P/Share
|
|
Feb 22
2023
|
Mikael Dolsten President R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
32,592
-7.69%
|
$1,368,864
$42.38 P/Share
|
|
Feb 22
2023
|
Albert Bourla Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
61,994
-14.96%
|
$2,603,748
$42.38 P/Share
|
|
Feb 22
2023
|
Jennifer B. Damico SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
7,944
-19.57%
|
$341,592
$43.04 P/Share
|
|
Feb 22
2023
|
Jennifer B. Damico SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
10,456
+32.63%
|
$313,680
$30.17 P/Share
|